IVVD
BEARISH
$1.76
Live
Invivyd, Inc. · NASDAQ
Target $10.0
(+468.2%)
$0.46
52W Range
$3.07
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$497.73M
P/E
N/A
ROE
-34.0%
Profit margin
-98.2%
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
90%
Invivyd exhibits critical financial weakness, highlighted by a Piotroski F-Score of 0/9, indicating a complete lack of fundamental improvement across all measured categories. While the company maintains a strong liquidity position with a Current Ratio of 7.24 and very low debt, it is suffering from extreme operational inefficiency with a profit margin of -98.25%. There is a stark disconnect between the analyst 'Strong Buy' consensus (Target $10.00) and the deterministic data, which shows consistent earnings misses and bearish insider activity.
Key Strengths
High Gross Margin (92.99%) suggesting strong product pricing potential
Strong short-term liquidity with a Current Ratio of 7.24
Very low leverage with a Debt/Equity ratio of 0.01
Positive year-over-year revenue growth of 24.50%
Significant upside gap relative to analyst price targets
Key Risks
Severe operational losses with a profit margin of -98.25%
Deterministic health failure (Piotroski F-Score 0/9)
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)
High valuation relative to sales (Price/Sales of 9.31) for a non-profitable entity
Bearish insider sentiment with multiple officer sales and zero buys
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
17
Weak
20
40
15
10
0
AI Verdict
Speculative/High Risk
Key drivers: Piotroski F-Score 0/9, Extreme negative profit margins, High liquidity runway, Bearish insider activity
Confidence
90%
Value
20/100
P/E is N/A; stock trades at a premium to book (2.05x) despite heavy losses.
Positives
- Low Debt/Equity
Watchpoints
- P/S ratio of 9.31 is high for current profitability
- No Graham Number available due to lack of earnings
Future
40/100
Growth is present in revenue, but not translating to the bottom line.
Positives
- Revenue growth of 24.5%
- Aggressive analyst price targets
Watchpoints
- Average earnings surprise of -858.33% over last 4 quarters
Past
15/100
Long-term trend is overwhelmingly negative despite recent volatility.
Positives
- 1Y price recovery of 248.5%
Watchpoints
- 5Y change of -91.6%
- Consistent history of earnings misses
Health
10/100
High cash reserves provide a runway, but the business model is currently value-destructive.
Positives
- Current Ratio 7.24
- Debt/Equity 0.01
Watchpoints
- Piotroski F-Score 0/9
- Negative ROE and ROA
Dividend
0/100
Dividend Strength 0/100.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.76
Analyst Target
$10.0
Upside/Downside
+468.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IVVD and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IVVD
Invivyd, Inc.
Primary
|
-91.6% | +46.1% | +248.5% | 0.0% | -7.4% | +37.5% |
|
AVR
Anteris Technologies Global Corp.
Peer
|
-8.8% | -8.8% | +40.4% | +17.2% | -21.5% | -6.6% |
|
ANGO
AngioDynamics, Inc.
Peer
|
-49.3% | +20.9% | +23.6% | +7.9% | +5.1% | +6.4% |
|
BWAY
BrainsWay Ltd.
Peer
|
+163.4% | +1289.2% | +184.8% | +61.0% | -3.2% | -7.8% |
|
AQST
Aquestive Therapeutics, Inc.
Peer
|
-27.7% | +432.4% | +47.8% | -20.4% | +5.2% | -4.7% |
IVV
Invivyd, Inc.
Primary
5Y
-91.6%
3Y
+46.1%
1Y
+248.5%
6M
0.0%
1M
-7.4%
1W
+37.5%
AVR
Anteris Technologies Global Corp.
Peer
5Y
-8.8%
3Y
-8.8%
1Y
+40.4%
6M
+17.2%
1M
-21.5%
1W
-6.6%
ANG
AngioDynamics, Inc.
Peer
5Y
-49.3%
3Y
+20.9%
1Y
+23.6%
6M
+7.9%
1M
+5.1%
1W
+6.4%
BWA
BrainsWay Ltd.
Peer
5Y
+163.4%
3Y
+1289.2%
1Y
+184.8%
6M
+61.0%
1M
-3.2%
1W
-7.8%
AQS
Aquestive Therapeutics, Inc.
Peer
5Y
-27.7%
3Y
+432.4%
1Y
+47.8%
6M
-20.4%
1M
+5.2%
1W
-4.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-8.0
PEG Ratio
N/A
P/B Ratio
2.05
P/S Ratio
9.31
EV/Revenue
5.11
EV/EBITDA
-4.98
Market Cap
$497.73M
Profitability
Profit margins and return metrics
Profit Margin
-98.25%
Operating Margin
-72.96%
Gross Margin
92.99%
ROE
-33.97%
ROA
-17.09%
Growth
Revenue and earnings growth rates
Revenue Growth
+24.5%
Earnings Growth
N/A
Q/Q Revenue Growth
+24.51%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
7.24
Strong
Quick Ratio
7.06
Excellent
Cash/Share
$0.8
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
93.4%
Op. Margin
-73.0%
Net Margin
-64.3%
Total Assets
$0.3B
Liabilities
$0.0B
Equity
$0.2B
Debt/Equity
0.15x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2025-11-06
$-0.06
+25.0% surprise
2025-08-14
$-0.12
-1300.0% surprise
2025-05-15
$-0.14
-1300.0% surprise
Healthcare Sector Comparison
Comparing IVVD against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-33.97%
This Stock
vs
-46.09%
Sector Avg
-26.3%
(Below Avg)
Profit Margin
-98.25%
This Stock
vs
-19.58%
Sector Avg
+401.7%
(Superior)
Debt to Equity
0.01
This Stock
vs
4.1
Sector Avg
-99.7%
(Less Debt)
Revenue Growth
24.5%
This Stock
vs
88.16%
Sector Avg
-72.2%
(Slower)
Current Ratio
7.24
This Stock
vs
3.58
Sector Avg
+102.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IVVD
Invivyd, Inc.
|
BEARISH | $497.73M | - | -34.0% | -98.2% | $1.76 | |
|
AVR
Anteris Technologies Global Corp.
|
BEARISH | $496.86M | - | -301.9% | -% | $5.11 | Compare |
|
ANGO
AngioDynamics, Inc.
|
BEARISH | $492.14M | - | -15.3% | -9.0% | $11.94 | Compare |
|
BWAY
BrainsWay Ltd.
|
NEUTRAL | $490.8M | 68.11 | 11.3% | 14.6% | $12.26 | Compare |
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $490.45M | - | -% | -188.1% | $4.02 | Compare |
IVVD
Invivyd, Inc.
BEARISH
Mkt Cap
$498M
P/E
-
ROE
-34.0%
Price
$1.76
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-18 | DUKE WILLIAM E. JR. | Chief Financial Officer | Sale | 40,627 | $63,350 |
| 2026-02-18 | ANDERSEN JILL | Officer | Sale | 67,710 | $105,581 |
| 2026-02-18 | ALLEN ROBERT D III | Officer | Sale | 37,581 | $58,600 |
| 2026-02-18 | GREEN JULIE | Officer | Sale | 40,627 | $63,350 |
| 2026-02-18 | LEE EDWARD TIMOTHY | Officer | Sale | 40,627 | $63,350 |
| 2026-02-13 | DUKE WILLIAM E. JR. | Chief Financial Officer | Stock Award | 99,000 | - |
| 2026-02-13 | ANDERSEN JILL | Officer | Stock Award | 165,000 | - |
| 2026-02-13 | ALLEN ROBERT D III | Officer | Stock Award | 99,000 | - |
| 2026-02-13 | GREEN JULIE | Officer | Stock Award | 99,000 | - |
| 2026-02-13 | LEE EDWARD TIMOTHY | Officer | Stock Award | 99,000 | - |
| 2025-11-19 | MCLAUGHLIN KEVIN F | Director | Purchase | 50,000 | $125,000 |
DUKE WILLIAM E. JR.
Chief Financial Officer
2026-02-18
40,627 shares
·
$63,350
ANDERSEN JILL
Officer
2026-02-18
67,710 shares
·
$105,581
ALLEN ROBERT D III
Officer
2026-02-18
37,581 shares
·
$58,600
GREEN JULIE
Officer
2026-02-18
40,627 shares
·
$63,350
LEE EDWARD TIMOTHY
Officer
2026-02-18
40,627 shares
·
$63,350
DUKE WILLIAM E. JR.
Chief Financial Officer
2026-02-13
99,000 shares
ANDERSEN JILL
Officer
2026-02-13
165,000 shares
ALLEN ROBERT D III
Officer
2026-02-13
99,000 shares
GREEN JULIE
Officer
2026-02-13
99,000 shares
LEE EDWARD TIMOTHY
Officer
2026-02-13
99,000 shares
MCLAUGHLIN KEVIN F
Director
2025-11-19
50,000 shares
·
$125,000
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
3 analysts
BTIG
2026-02-26
Buy
Buy
BTIG
2025-12-23
Buy
Buy
BTIG
2025-12-22
Buy
D. Boral Capital
2025-11-25
Buy
Hold
HC Wainwright & Co.
2025-11-03
Buy
Buy
HC Wainwright & Co.
2025-10-31
Buy
Buy
Past News Coverage
Recent headlines mentioning IVVD from our newsroom.
Newest → oldest
No matching news yet.